TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02358343

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Engagement Interview
Description: An Engagement Interview will comprise a one-on-one session with the patient, during which the health-care provider will use reflective statements and non-judgmental listening techniques, will explore barriers to treatment, and will help patient articulate ambivalence about engaging in treatment. This session will be enhanced with a 40-minute DVD that the subject will watch with the therapist in the dialysis facility. The subject will be encouraged to take the DVD home with them and watch it with their family members as well.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy (CBT) is a short-term psychotherapy that will focus on how the individual is thinking, behaving, and communicating today rather than on their childhood experience. The therapist will assist the patient in identifying specific distortions (cognitive assessment) and biases in thinking and will provide guidance on how to change this thinking. During the course of intervention, study subjects will undergo assessment of severity of depressive symptoms using Quick Inventory of Depressive Symptoms - Self-Report (QIDS-SR) every two weeks for the first six weeks (weeks 0, 2, 4, and 6) and every three weeks for the next six weeks (weeks 9 and 12).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antidepressant Drug Therapy
Description: The site investigators will prescribe sertraline drug at a starting dose of 25 mg oral tablets. Dose titration will be implemented using standardized assessments of depressive symptoms and drug side effects; and the research team and the patient make joint decisions to maintain, increase, or decrease the dose. This will help establish the highest effective but tolerable dose tailored for each patient. The QIDS-SR scale will be used to assess the clinical response for dose titration. The FIBSER scale will be used to assess side effects and the degree to which they interfere with day-to-day functions. The participant-specific dose at week 6, up to a maximum of 200 mg/d, will be continued for the remaining 6 weeks.
Study: NCT01249365

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK580299 (Cervarix)
Description: 3-dose schedule intramuscularly vaccination
Study: NCT01439230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 10 mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aricept®
Description: 10 mg Tablet
Study: NCT00417404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aquasol A
Description: IM Aquasol A 10,000IU three times weekly
Study: NCT01011946

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Mammography
Description: Patients will receive bilateral (both sides) breast and axillary PEM scans, bilateral mammography, DCE-MRI, US of the breast and axilla (the side of the affected breast), and ultrasound guided biopsy of axillary lymph node if suspicious. Various PEM views will be performed on both your breast and axilla (underarm).
Study: NCT04222946

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle
Study: NCT03427034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BladderLight®
Description: Using a cell collection device to look for the presence of bladder cancer cells

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BladderLight®
Description: Using a cell collection device to look for the presence of bladder cancer cells
Study: NCT04818931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin Injection
Description: cefazolin 2 g or clindamycin 900 mg in case of penicillin allergy
Study: NCT01644916

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Integrated care
Description: Integrated care will be provided with management of multifaceted group including, nurse educators, doctors, case manager and psychologists.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Usual control
Description: Usual control group will be provided with usual standard procedures for management of COPD and psychiatric comorbidities.
Study: NCT02057939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: 160 mg orally once daily for six months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation
Description: Two injections each lasting three months, for a total of six months of androgen deprivation therapy. Doctor will help determine which androgen deprivation drug to use.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Daily (Monday-Friday) for 6-8 weeks, final dose of approximately 66 Gy
Study: NCT00344760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Description: subcutaneously twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz, lamivudine, and tenofovir
Description: Efavirenz -600mg once daily, lamivudine- 300mg once daily, and tenofovir 300mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz, lamivudine, and tenofovir
Description: Efavirenz -600mg once daily, lamivudine- 300mg once daily, and tenofovir 300mg once daily
Study: NCT02249026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BZDs + opiate exposure treated with BPN
Description: These infants will have been exposed not only to opiates but also to BZDs during pregnancy. Administration of Buprenorphine: The solution will be administered under the tongue followed by the insertion of a pacifier to reduce swallowing. Dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed. If the infant's withdrawal is not controlled, clonidine will be used as adjunct therapy. The initial dose of clonidine is 6 mcg/kg/day in 4 divided doses given every 6 hours. If signs of withdrawal are not controlled, the dose may be increased by 3mcg/kg/day to a maximum 12 mcg/kg/day divided q 6 hrs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opiates exposure treated with BPN
Description: These infants will have been exposed not only to opiates during pregnancy. Administration of Buprenorphine: The solution will be administered under the tongue followed by the insertion of a pacifier to reduce swallowing. Dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed. If the infant's withdrawal is not controlled, clonidine will be used as adjunct therapy. The initial dose of clonidine is 6 mcg/kg/day in 4 divided doses given every 6 hours. If signs of withdrawal are not controlled, the dose may be increased by 3mcg/kg/day to a maximum 12 mcg/kg/day divided q 6 hrs.
Study: NCT01655745

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG PET/MR
Description: All patients will undergo a gadolinium enhanced MRI with simultaneous acquisition of FDG-PET prior to planned radical cystectomy and pelvic lymph node dissection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG PET/MR
Description: All patients will undergo a gadolinium enhanced MRI with simultaneous acquisition of FDG-PET prior to planned radical cystectomy and pelvic lymph node dissection
Study: NCT03854851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldebain
Description: In Naldebain group, patients will be injected with Naldebain (150 mg/2 ml, IM injection) between 12 and 24 hours prior to surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morpine
Description: In Morphine group, patients will receive morphine as needed after surgery.
Study: NCT01170221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA
Description: Oral TR-701 FA 200 mg once daily for six days followed by four days of placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Oral Linezolid 600 mg twice daily for 10 days
Study: NCT04373213

Intervention type: DIAGNOSTIC_TEST
Intervention: Pleth variability index
Description: The usefulness of Pleth variability index in predicting fluid response in patients with COVID 19

Intervention type: DIAGNOSTIC_TEST
Intervention: Pleth variability index
Description: The usefulness of Pleth variability index in predicting fluid response in patients with COVID 19
Study: NCT04179019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine (10mg daily, as tolerated by blood pressure parameters) for 2 weeks
Study: NCT02899624

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Extra blood draw samples

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Extra blood draw samples

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: additional tissue samples

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: additional tissue samples
Study: NCT01045928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative study

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: nucleic acid sequencing
Description: Correlative study

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Correlative study
Study: NCT02702154

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS
Description: 20 Hz active stimulation, twice daily

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS
Description: 1 Hz active stimulation, twice daily

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham stimulation, twice daily
Study: NCT00773656

Intervention type: OTHER
Intervention: Whole blood sample
Description: 70 ml per patient for collection of biological sample
Study: NCT01045928

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study
Study: NCT02613520

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PfSPZ Challenge (for CHMI)
Description: live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PfSPZ Challenge (for CHMI)
Description: live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
Study: NCT04489004

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Driver ablation+CPVI
Description: Patients receive driver ablation and CPVI (circumferential pulmonary vein isolation).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stepwise ablation
Description: Patients receive stepwise ablation.
Study: NCT02347852

Intervention type: DRUG
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Stivarga is available as tablets (40 mg). It is taken in four-week treatment cycles at a recommended starting dose of 160 mg once every day for three weeks, followed by a week off.
Study: NCT03530202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Description: Participants will consume creatine monohydrate powder (Creapure, AlzChem AG, Trostberg, Germany) every day for 8 weeks. On training days participants will consume supplement immediately after each training session (\~ 5 minutes) mixed in water as post-exercise creatine ingestion enhances its uptake into muscle and promotes increased muscle mass. On non-training days, supplements will be consumed at the participant's leisure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin Powder
Description: Participants will consume Maltodextrin Powder (Globe Plus 10 DE Maltodextrin Powder, Univar Canada) every day for 8 weeks. On training days participants will consume supplement immediately after each training session (\~ 5 minutes) mixed in water. On non-training days, supplements will be consumed at the participant's leisure.
Study: NCT04000022

Intervention type: DEVICE
Intervention: intermittent theta burst stimulation (iTBS)
Description: 20 sessions of iTBS

Intervention type: DEVICE
Intervention: intermittent theta burst stimulation (iTBS)
Description: 20 sessions of iTBS
Study: NCT01605201

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tissue engineered cartilage graft
Description: Autologous nasal chondrocytes expanded in vitro and cultured in a collagen type I//III scaffold
Study: NCT03796884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study: NCT04095442

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cepacol
Description: Twice-daily use of Cepacol per the manufacturer's guidelines
Study: NCT02613520

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge (for CHMI)
Description: live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PfSPZ Challenge (for CHMI)
Description: live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
Study: NCT00198328

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Medpulser Electroporation with Bleomycin
Description: Patients receive injections of Bleomycin Sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area followed by electroporation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Excision
Description: Patients have their tumor surgically removed.
Study: NCT01490918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: Acarbose 50mg b.i.d at first, at the 2nd week 50mg t.i.d and the 4th week, 100mg tid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acarbose
Description: acarbose placebo

Intervention type: DRUG
Group type: OTHER
Intervention: placebo metformin
Description: metformin placebo
Study: NCT03659110

Intervention type: BIOLOGICAL
Intervention: HPV 4
Description: 1000 subjects will be received the HPV 4 vaccine
Study: NCT00898170

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: myoma removal
Description: surgical removal of myoma by hysterectomy
Study: NCT06160141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Resistance training program. The RT program was performed over 48 weeks, three times per week (Mondays, Wednesdays, and Fridays), during the morning, in the University fitness facility. Participants were personally supervised by Physical Education professionals (1-2 supervisors per exercise) with substantial RT experience to ensure consistent and safe exercise performance.~Participants performed four exercises for the trunk and upper limbs and four exercises for the lower limbs in three sets of 8-12 repetitions. T Rest intervals were 1-2 and 2-3 min between sets and exercises. The training load was individually adjusted for each exercise weekly, according to the number of repetitions performed during the last training session, to ensure that the subjects kept performing at the ideal intensity for the repetition zone. In these situations, training loads were increased by 2-5% for upper-limb exercises and 5-10% for lower-limb exercises.
Study: NCT03117959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stryker ShapeMatch Technology
Description: Will use this patient-specific guide for alignment with Stryker Triathlon Custom Fit Knee.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Stryker Triathlon Custom Fit Knee
Study: NCT04095442

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Tom's Natural Mouthwash
Description: Twice-daily use of Tom's Natural Mouthwash per the manufacturer's guidelines
Study: NCT02223429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: 1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
Study: NCT04681729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893
Description: Pharmaceutical form: Injection solution Route of administration: Subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Injection solution Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non sedating H1-antihistamine
Description: Pharmaceutical form: Tablet Route of administration: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non sedating H1-antihistamine
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study: NCT02757092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based Pulmonary Rehabilitation
Description: (1) breathing exercises (pursed-lip and diaphragmatic breathing) and coughing exercises, (2) aerobic exercises (upper and lower limb exercises and walking), (3) incentive spirometry training (Triflo-II), and (4) threshold load training of the inspiratory muscle. In the first stage (0-2 weeks), the aerobic exercise intensity was targeted to reach 10-11 points on the 20-point Borg rating of perceived exercise (RPE) scale. Patients raised their upper limbs while simultaneously performing lower-limb stepping at place for 20 min; in addition, they walked at a comfortable speed for 15 min twice per day. Incentive spirometry training (Triflo-II) was performed 8-10 times per hour. We used a threshold load trainer for inspiratory muscle training (30 breaths each time, twice per day) with the initial pressure set at 25%-30% of the maximum inspiratory pressure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based Pulmonary Rehabilitation
Description: (1) breathing exercises (pursed-lip and diaphragmatic breathing) and coughing exercises, (2) aerobic exercises (upper and lower limb exercises and walking), (3) incentive spirometry training (Triflo-II), and (4) threshold load training of the inspiratory muscle. In the first stage (0-2 weeks), the aerobic exercise intensity was targeted to reach 10-11 points on the 20-point Borg rating of perceived exercise (RPE) scale. Patients raised their upper limbs while simultaneously performing lower-limb stepping at place for 20 min; in addition, they walked at a comfortable speed for 15 min twice per day. Incentive spirometry training (Triflo-II) was performed 8-10 times per hour. We used a threshold load trainer for inspiratory muscle training (30 breaths each time, twice per day) with the initial pressure set at 25%-30% of the maximum inspiratory pressure.
Study: NCT03148587

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-assessment: MLPT
Description: Patients enrolled in the study will self-assess the outcomes of their medical abortion using the multi-level pregnancy test.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-assessment: LSPT
Description: Patients enrolled in the study will self-assess the outcomes of their medical abortion using the low sensitivity pregnancy test.
Study: NCT00908622

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous autologous myoblast implantation
Description: Endocavity implantation of autologous myoblasts

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cardiac revascularization
Description: Cardiac revascularization
Study: NCT04159818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg flat-dose, every 2 weeks. From 20 weeks onwards, nivolumab will be administered every 4 weeks with a flat-dose of 480 mg starting from week 20 onwards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg flat-dose, every 2 weeks. From 20 weeks onwards, nivolumab will be administered every 4 weeks with a flat-dose of 480 mg starting from week 20 onwards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg flat-dose, every 2 weeks. From 20 weeks onwards, nivolumab will be administered every 4 weeks with a flat-dose of 480 mg starting from week 20 onwards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 40mg/m2, weekly for two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose doxorubicin
Description: 15mg flat dose, weekly for 8 weeks
Study: NCT02006498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sillymarin
Description: Sillymarin is derived from the milk thistle plant, Silybum marianum, a herbal remedy that has been used for centuries for diseases of the liver. It is a complex mixture of 6 major flavonolignans (silybins A and B, isosilybins A and B, silychristin, and silydianin), as well as other minor polyphenolic compounds.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule with same appearances as study drug
Study: NCT03970018

Intervention type: OTHER
Intervention: Intra-peritoneal pressure
Description: Measurement of intra-peritoneal pressure
Study: NCT01759160

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Marsh Plasma TCI with high initial target
Description: plasma target-controlled infusion in Marsh model(n=30) with an initial target concentration of 4 μg/ml. Target was then reset and gradually titrated to a sedation level with narcotrend index below 64.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Schnider Plasma TCI with high initial target
Description: plasma target-controlled infusion in Schnider model(n=30) with an initial target concentration of 4 μg/ml. Target was then reset and gradually titrated to a sedation level with narcotrend index below 64.